JP2010519274A - ＴＮＦおよびα−ガラクトシルセラミドを使用する併用療法 - Google Patents

ＴＮＦおよびα−ガラクトシルセラミドを使用する併用療法 Download PDF

Info

Publication number
JP2010519274A
JP2010519274A JP2009550701A JP2009550701A JP2010519274A JP 2010519274 A JP2010519274 A JP 2010519274A JP 2009550701 A JP2009550701 A JP 2009550701A JP 2009550701 A JP2009550701 A JP 2009550701A JP 2010519274 A JP2010519274 A JP 2010519274A
Authority
JP
Japan
Prior art keywords
tnf
galcer
treatment
galactosylceramide
administration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2009550701A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010519274A5 (https=
Inventor
ブロッカート，ペーター
エレヴァオト，ディルク
ヒューグ，レアンダー
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw Vib Vzw
Universiteit Gent
Original Assignee
Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw Vib Vzw
Universiteit Gent
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw Vib Vzw, Universiteit Gent filed Critical Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw Vib Vzw
Publication of JP2010519274A publication Critical patent/JP2010519274A/ja
Publication of JP2010519274A5 publication Critical patent/JP2010519274A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/191—Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2009550701A 2007-02-21 2008-02-20 ＴＮＦおよびα−ガラクトシルセラミドを使用する併用療法 Pending JP2010519274A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP07102787 2007-02-21
PCT/EP2008/052055 WO2008101951A1 (en) 2007-02-21 2008-02-20 Combination therapy using tnf and alfa-galactosyl ceramide

Publications (2)

Publication Number Publication Date
JP2010519274A true JP2010519274A (ja) 2010-06-03
JP2010519274A5 JP2010519274A5 (https=) 2011-04-07

Family

ID=39495301

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009550701A Pending JP2010519274A (ja) 2007-02-21 2008-02-20 ＴＮＦおよびα−ガラクトシルセラミドを使用する併用療法

Country Status (6)

Country Link
US (1) US7959907B2 (https=)
EP (1) EP2117583B1 (https=)
JP (1) JP2010519274A (https=)
AU (1) AU2008219269B2 (https=)
CA (1) CA2678088A1 (https=)
WO (1) WO2008101951A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7959907B2 (en) 2007-02-21 2011-06-14 Vib Vzw Method of treating cancer by combination therapy using TNF and alpha-galactosylceramide
WO2016065353A1 (en) * 2014-10-24 2016-04-28 University Of Miami Combination therapy with fenofibrate and 2-deoxyglucose or 2-deoxymannose

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4677063A (en) 1985-05-02 1987-06-30 Cetus Corporation Human tumor necrosis factor
US4677064A (en) 1984-11-09 1987-06-30 Cetus Corporation Human tumor necrosis factor
JPH0559081A (ja) 1991-08-29 1993-03-09 Kirin Brewery Co Ltd 新規スフインゴ糖脂質、その製造法および使用
US6001619A (en) 1995-10-04 1999-12-14 Cold Spring Harbor Laboratory Ubiquitin ligases, and uses related thereto
EP1192174A4 (en) 1999-06-11 2002-08-28 Univ New York State Res Found ANTAGONISTS OF BMP AND TGF BETA SIGNAL PATHS
AU2003251518B2 (en) 2002-06-13 2009-07-02 New York University Synthetic C-glycolipid and its use for treating cancer infectious diseases and autoimmune diseases
WO2005003167A1 (en) 2003-07-01 2005-01-13 Vib Vzw Ubiquitinated tnf receptor 2 and its uses
EP1784196B1 (en) 2004-08-27 2016-12-21 Albert Einstein College Of Medicine Of Yeshiva University Ceramide derivatives as modulators of immunity and autoimmunity
US7959907B2 (en) 2007-02-21 2011-06-14 Vib Vzw Method of treating cancer by combination therapy using TNF and alpha-galactosylceramide

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
JPN6012054914; Ｅｕｒ．Ｊ．Ｂｉｏｃｈｅｍ．，　１９８５，　Ｖｏｌ．　１５２，　Ｎｏ．　３，　Ｐ．　５１５-５２２ *
JPN6012054918; Ｃｌｉｎ．Ｅｘｐ．Ｍｅｔａｓｔａｓｉｓ，　２０００，　Ｖｏｌ．　１８，　Ｎｏ．　２，　Ｐ．　１４７-１５３ *
JPN6012054920; Ｃａｎｃｅｒ　Ｓｃｉ．，　２００８．Ｊａｎ．，　Ｖｏｌ．　９９，　Ｎｏ．　１，　Ｐ．　１１３-１２０ *

Also Published As

Publication number Publication date
AU2008219269B2 (en) 2012-10-25
AU2008219269A1 (en) 2008-08-28
EP2117583A1 (en) 2009-11-18
US20100166697A1 (en) 2010-07-01
US7959907B2 (en) 2011-06-14
EP2117583B1 (en) 2013-05-22
CA2678088A1 (en) 2008-08-28
WO2008101951A1 (en) 2008-08-28

Similar Documents

Publication Publication Date Title
Colombo et al. Interleukin-12 in anti-tumor immunity and immunotherapy
Younes et al. Interferon‐γ therapy: Evaluation of routes of administration and delivery systems
KR101192136B1 (ko) 혈액 줄기 세포의 동원에 유효한 ｇ-ｃｓｆ와 ｐｌｇｆ의조합 약제
US20040131588A1 (en) Formulation having mobilising activity
EP2117583B1 (en) Combination therapy using TNF and alpha-galactosyl ceramide
Negrier et al. Phase I trial of recombinant interleukin-2 followed by recombinant tumor necrosis factor in patients with metastatic cancer
Takahashi et al. Induction of tolerance allows separation of lethal and antitumor activities of tumor necrosis factor in mice
JP2528114B2 (ja) 腫瘍壊死因子を含んで成る組成物
US5096707A (en) Flavone-8-acetic acid and interleukin-2 in a method of treating certain cancers
ES2448837T3 (es) Agente que comprende G-CSF para la prevención y el tratamiento de neuropatía periférica diabética
Ohno Granulocyte colony-stimulating factor, granulocyte-macrophage colony-stimulating factor and macrophage colony-stimulating factor in the treatment of acute myeloid leukemia and acute lymphoblastic leukemia
CN101068564B (zh) 含有vegf抑制剂与5fu或其中一种衍生物的抗肿瘤组合物
Sone et al. Local lnterleukin-2 Therapy for Cancer, and Its Effector Induction Mechanisms
Balemans et al. PEG‐IL‐2 therapy of advanced cancer in the guinea pig. Impact of the primary tumor and beneficial effect of cyclopphosphamide
JP2010529984A (ja) 癌を治療するためのインターフェロンアルファ逐次レジメン
Teicher et al. Optimal scheduling of interleukin‐12 and fractionated radiation therapy in the murine lewis lung carcinoma
van Moorselaar et al. Synergistic antitumor effects of rat γ-interferon and human tumor necrosis factor α against androgen-dependent and-independent rat prostatic tumors
Frankfurt et al. Growth factors in leukemia
Gottlieb Cytokine manipulation of the immune response in the treatment of human acute leukaemia
JPH09510737A (ja) 化学療法剤を増強するためのｉｌ−４の使用
TW202019440A (zh) 用於治療癌症之組合療法
Krosnick et al. Studies of the mechanisms of toxicity of the administration of recombinant tumor necrosis factor α in normal and tumor-bearing mice
Ravandi et al. CYTOKINES IN THE TREATMENT OF ACUTE
US9687472B2 (en) Use of antioxidants as an adjuvant to immune stimulators to augment tumor immunity and prevent toxicity associated with oxidative stress
Lasek et al. Augmentation of antitumor efficacy by the combination of actinomycin D with tumor necrosis factor-alpha and interferon-gamma on a melanoma model in mice

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110218

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20110218

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20121023

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20130423